Alto Neuroscience, Inc.
ANRO- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001999480
In the last 90 days, Alto Neuroscience, Inc. insiders filed 0 open-market purchases and 1 sale; 114 institutions reported holding it in 13F filings for Q2 2026, worth $777.6M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Alto Neuroscience, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 80 | 77 | −3 |
| Shares | 17.3M | 16.8M | −538.6K (−3.1%) |
| Value | $38.1M | $67.4M | +$29.3M (+77.1%) |
New holders (9)
Institutions that held Alto Neuroscience, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Perceptive Advisors LLC | 155,366 | $624.6K | 0.02% |
| Citadel Advisors LLC | 37,152 | $149.4K | 0.00% |
| XTX Topco Ltd | 15,746 | $63.3K | 0.00% |
| Northwestern Mutual Wealth Management Co | 1,450 | $5.83K | 0.00% |
| Advisory Services Network, LLC | 802 | $3.22K | 0.00% |
| North Star Investment Management Corp. | 174 | $699 | 0.00% |
| SRS Capital Advisors, Inc. | 42 | $169 | 0.00% |
| Optiver Holding B.V. | 20 | $80 | 0.00% |
| Cloud Capital Management, LLC | 8 | $0 | 0.00% |
Sold out (12)
Institutions that held Alto Neuroscience, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Charles Schwab Investment Management Inc | 115,263 | $253.6K |
| Cantor Fitzgerald, L. P. | 40,000 | $88.0K |
| Y-Intercept (Hong Kong) Ltd | 38,597 | $84.9K |
| Jain Global LLC | 21,171 | $46.6K |
| DRW Securities, LLC | 14,080 | $31.0K |
| Ground Swell Capital, LLC | 12,447 | $27.4K |
| Citigroup Inc | 2,303 | $5.07K |
| Wells Fargo & Company | 351 | $772 |
| Clearstead Advisors, LLC | 178 | $392 |
| Essential Partners LLC | 8 | $18 |
| Caitong International Asset Management Co., Ltd | 2 | $4 |
| IFP Advisors, Inc | 1 | $2 |